Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Biohaven Pharmaceutical Holding Company Ltd
BHVN | US
10.21
USD0.29
2.92%
BHVN | US
Loading StockChartView...
About Biohaven Pharmaceutical Holding Company Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
10.21
Open
11.89
High
12.10
Low
9.26
Biohaven Ltd. a clinical-stage biopharmaceutical company focuses on discovering developing and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000 a potassium channel activator for the treatment of focal epilepsy; BHV-7010 a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat an oral myeloperoxidase inhibitor which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa an anti-myostatin adnectin which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
View LessBHVN | US
Risk
64.9
Sharpe
-0.75
Luna's Score
49/100
Recommendation
Hold
Luna says (BHVN | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
65.3%1 month
64.9%3 months
82.1%6 months
101.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
13.93
Debt to equity
0.08
Debt to assets
0.05
Ent. to EBITDA
-2.19
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-774.44M
MarketCap
1.03B
MarketCap(USD)
1.03B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-193.67
Short ratio
7.11
Short perc.
10.71
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.84
Range1M
3.82
Range3M
4.75
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
2.70
Price X volume
61.09M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.19 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 13.93 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 82.14 | 72.80 | Par |
| Debt to Equity | 0.08 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 1.03B | 3.66B | Emerging |
